Our stem cells are the only umbilical cord MSCs that have gotten an IND designation from the US FDA. Human umbilical cord tissue-derived mesenchymal stem cells (MSCs) that were isolated and grown in our laboratory to generate master cell banks are presently being used. These cells serve as the preparatory material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient)

To begin with your assessment, please complete our online patient application. If you still have queries, please feel free to contact us today!

Once our medical crew has received your medical application, it generally takes about 5 working days to review it. As soon as the review is complete, we will contact you to talk over available treatment alternatives (if any) and to request any supplementary medical records. Once approved, a patient is programmed for the earliest available appointment that is suitable for him or her. If you are not approved for treatment centered upon your medical history, you will be informed by email.

All stem cell treatments are implemented at some of the finest clinics. Many of the hospitals and clinics are new and have good, contemporary facilities. Maximum of the medical staff is trained in other nations such as the US so they are aware of all the newest developments and technologies. When equated with other nations, the standard of healthcare is considered to be high. Full care is offered at the hospitals we are allied with.

Yes. According to each patient’s prerequisites, physical therapy will be suggested by our medical team and offered during the course of treatment.

Insurance enterprises do not cover adult stem cell therapy.

Treatment cost depends on the kind of treatment required and will be discussed with you following patient application and analysis. The cost of treatment takes account of the treatment itself plus a hotel room with breakfast, WIFI, conveyance from and to the airport with VIP airport gate service and accelerated customs clearance upon arrival. If you would like to get an estimated idea about how much a specific treatment protocol may cost, please give us a call and one of our patient coordinators will be pleased to assist you.

Usually speaking, in addition to the initial pain at the injection site, the patient will not experience any uneasiness. Less than 10% of (mostly lumbar puncture) patients have developed a minor fever, headache, nausea or vomiting. However, these side-effects have never lasted than three days and typically resolve within 24 hours. No long-term negative side-effects have been reported by far.

Every single treatment and patient is unique, and there is no assurance of what outcomes will be seen or how speedily they might be observed. Some patients have remarked on changes during the course of their treatment, others have experienced improvement within 6 months of returning home. Some patients do not improve at all after the treatment.

Alcohol consumption and cigarette smoking can both be damaging to new progenitor stem cells. It is greatly sagacious that individuals do not smoke or drink during their treatment.

Typically, the doctors do not recommend any medicine as a part of your treatment. However, they do recommend a circulating stem cell enhancing supplement regime following treatment.

Treatment decorum differs by disease. Each patient’s physical condition and other medical aspects also play roles. Most protocols last for 1-4 weeks and comprise of 3-16 sittings. Typical treatment protocols can be viewed on separate pages.

The body’s immune system is unable to distinguish umbilical cord-derived mesenchymal stem cells as foreign and consequently they are not rejected. These stem cells have been administered thousands of times at our clinic and there has never been a single instance of rejection (graft vs. host disease). As a matter of fact, mesenchymal stem cells are permitted to treat graft vs. host disease in Canada and New Zealand. Umbilical cord-derived mesenchymal stem cells also multiply/differentiate more proficiently than “older” cells, such as those found in the fat and thus, they are considered to be more “potent”.

Every patient’s bone marrow is collected by a qualified hematologist with an anesthesiologist. The bone marrow is drawn into syringes that are inserted via the skin on the back and into the hip bones. Bone marrow collection normally takes about 1.5 hours. Bone marrow is implemented in a hospital setting on an out-patient basis under light general anesthesia. We get cord donations from healthy females. Our donors sign a consent form, fill out a detailed survey and give a blood sample. The mothers’ blood and the cord blood go through all-embracing testing for HIV, STD’s, hepatitis, etc.

Adult stem cells are not embraced by the controversy surrounding fetal and embryonic stem cells. Both the Catholic Church and the Southern Baptist Church have issued papers which in fact encourage research and the use of adult stem cells in the treatment of human sickness, as an ethically suitable alternative to the use of the ethically challenged fetal and embryonic stem cells.

Fundamentally, stem cells are progenitor cells which are adept of regeneration and differentiation into a catholic array of specialized cell types. Once vaccinated, stem cells follow inflammatory signals from impaired tissues and have several ways of repairing these impaired parts. Umbilical cord mesenchymal stem cells act via anti-inflammatory activity, immune modulating capability and the aptitude to stimulate regeneration can be screened and selected.

The main cells types leveraged for stem cell therapy at Viezec are:

• Mesenchymal Stem Cells – preferably suited for treating systemic autoimmune and inflammatory disorders. They also play a noteworthy role in regenerating injured tissue.
• Hematopoietic Stem Cells – best suitable for tissue regeneration because of the synergistic effect of CD34+ cells’ revascularization characteristics in concert with the tissue overhauling function of the mesenchymal stem cells.

The Viezec uses adult stem cells derived from:

• Human Umbilical Cord Tissue – an opulent source of mesenchymal stem cells (MSCs).
• Bone Marrow – a good source of CD34+ stem cells (but a poor source of mesenchymal stem cells).

As we both of these stem cells sources at our disposal, including the aptitude to inflate them into larger numbers when specified, we can select optimum stem cell sources for each disease/condition and, if essential, each individual we treat. However, because human umbilical cord tissue is a healthier source of MSCs, we no longer treat patients with MSCs from fat tissue.